Login to Your Account

NewCo News

Advaxis Uses Listeria Bug to Launch Attack on Cancer Cells

By Catherine Shaffer
Staff Writer

Wednesday, June 6, 2012
Advaxis Inc. reported positive preliminary results from a Phase II trial of its human papillomavirus (HPV) immunotherapy product, ADXS-HPV, at the American Society of Clinical Oncology meeting in Chicago this week.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription